1251 ET - Hims & Hers Health could have an opportunity coming its way as the government focuses on pushing peptide availability, Jefferies analysts say in a note. Hims & Hers likely wouldn't commercialize peptide products instantaneously after the Food and Drug Administration's meeting in July regarding the drug class, given management is taking a methodical approach to their strategy in the category, the analysts say. However, Hims & Hers likely has the assets--including compounding pharmacies--and capabilities to rollout a portfolio of peptide products months after any FDA approval, they say. The analysts expect the stock could get a boost on the outcome of the FDA's meeting, though note that shares will largely hinge on the company's overall execution after its recent strategic shift in its weight-loss business. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 12, 2026 12:51 ET (16:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.